[Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system].
Derer
W
W
Klinik und Poliklinik für Kardiologie und Nephrologie, HELIOS-Klinikum Berlin-Buch. wolfgang.derer@helios-kliniken.de
Dechend
R
R
Müller
D N
DN
D000419:Albuminuria / Q000175:diagnosis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D000077545:Eplerenone; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006929:Hyperaldosteronism / Q000145:classification / Q000188:drug therapy*; D006973:Hypertension / Q000188:drug therapy; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects*; D013148:Spironolactone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016896:Treatment Outcome
D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone
Welchen Stellenwert haben sie in der antihypertensien Therapie?